Diabetes News/Recent Literature Review/ First Quarter 2018
DOI:
https://doi.org/10.2015/hc.v13i1-4.858Abstract
Metformin Treatment in Patients with Type 2 Diabetes and Chronic Kidney Disease Stages 3A, 3B, or 4
The safety of metformin was examined in moderate and severe chronic kidney disease (CKD)( stages 3A/3B and 4, eGFR 59-45, 44-30, and <15 mL/min/1.72 m2 , respectively). Three metformin doses were examined: 1,500mg (0.5 g in the morning [qam]+ 1g in the evening [qpm]) in CKD3A, 1,000 mg (0.5g qam + o.5 g qpm ) in CKD3B, and 500 mg (qam) in CKD 4. After 4 months on these regimens, patients displayed stable metformin concentrations that never exceeded the safe upper limit of 5.0 mg/L. Hyperlactatemia was absent, and HbA1c levels did not change. The study provided solid basis for the continuing metformin treatment in patients with moderate or severe CKD, supporting the recent guidelines on metformin treatment, providing that the dose is adjusted to the eGFR (Lalau JD et al, Diabetes Care 2018;43:547-553).
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
